Spruce Biosciences, Inc. (SPRBD)
OTCMKTS · Delayed Price · Currency is USD
7.00
-0.50 (-6.67%)
At close: Aug 29, 2025
Spruce Biosciences Revenue
Spruce Biosciences had revenue of $1.30M in the twelve months ending June 30, 2025, down -86.43% year-over-year. In the year 2024, Spruce Biosciences had annual revenue of $4.91M, down -51.32%.
Revenue (ttm)
1.30M
Revenue Growth
-86.43%
P/S Ratio
3.03
Revenue / Employee
144.33K
Employees
21
Market Cap
3.94M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.91M | -5.18M | -51.32% |
Dec 31, 2023 | 10.09M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |
Spruce Biosciences News
- 16 days ago - Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - Business Wire
- 16 days ago - Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 5 weeks ago - Spruce Biosciences Announces Reverse Stock Split - Business Wire
- 5 weeks ago - HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder - GlobeNewsWire
- 2 months ago - Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market - Business Wire
- 4 months ago - Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - Business Wire
- 4 months ago - Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript) - Seeking Alpha
- 4 months ago - Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire